Show simple item record

dc.contributor.authorCooper, David A.
dc.contributor.authorCordery, Damien V.
dc.contributor.authorZajdenverg, Roberto
dc.contributor.authorRuxrungtham, Kiat
dc.contributor.authorArastéh, Keikawus
dc.contributor.authorBergmann, Frank
dc.contributor.authorAndrade Neto, José L. de
dc.contributor.authorScherer, Joseph
dc.contributor.authorChaves, Ricardo L.
dc.contributor.authorRobinson, Patrick
dc.date.accessioned2020-09-09T15:51:28Z
dc.date.accessioned2023-05-10T17:57:26Z
dc.date.available2020-09-09T15:51:28Z
dc.date.available2023-05-10T17:57:26Z
dc.date.created2016-01-05
dc.identifierhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0144917spa
dc.identifier.issn1932-6203 (Electrónico)spa
dc.identifier.urihttps://hdl.handle.net/20.500.12032/96877
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.languageInglésspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourcePLoS ONE; Vol. 11 Núm. 1 (2016)spa
dc.titleTipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients : A Randomized, Multinational, Multicenter Trialspa
dc.typeinfo:eu-repo/semantics/article


Files in this item

FilesSizeFormatView
journal.pone.0144917.PDF748.3Kbapplication/pdfView/Open

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/

© AUSJAL 2022

Asociación de Universidades Confiadas a la Compañía de Jesús en América Latina, AUSJAL
Av. Santa Teresa de Jesús Edif. Cerpe, Piso 2, Oficina AUSJAL Urb.
La Castellana, Chacao (1060) Caracas - Venezuela
Tel/Fax (+58-212)-266-13-41 /(+58-212)-266-85-62

Nuestras redes sociales

facebook Facebook

twitter Twitter

youtube Youtube

Asociaciones Jesuitas en el mundo
Ausjal en el mundo AJCU AUSJAL JESAM JCEP JCS JCAP